CURE Pharmaceutical & Therapix Biosciences Signs MOU with Israel’s Assuta Medical Centers to Develop First-in-Class Therapeutic Products in Fields of Personalized Medicine & Cannabinoids

CURE Pharmaceutical (OTCQB:CURR), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company and Therapix Biosciences (Nasdaq: TRPX ), a specialty clinical-stage pharmaceutical company dedicated to the development of cannabinoid-based drugs headquartered in Israel, announced today that they signed a memorandum of understanding (MOU) to enter into a research collaboration with Assuta Medical Centers Ltd. 

SinglePoint Inc. (OTC:SING) Eliminates Debt and Gains Additional $1m in Funding

SinglePoint, Inc. (OTC: SING) has raised more than $300,000 and has signed a Letter of Intent to secure additional funding of $1 million.

Today's update follows news of the Company's recent Letter of Intent to acquire a stake in Convectium, which created the world's first machine capable of filling cartridges or disposables en mass for wholesale distribution to cannabis dispensaries.

Disruptive Technology: Here’s The Future $PKG $WEED $MYM $PTNYF

Ding Dong: Here’s Your Pot. In the world of new and disruptive technologies, there are a few ideas that just make a lot of sense to everyone. And sure enough, several have become overnight sensations creating unimaginable wealth (especially for early investors), while changing the landscape completely. The funny thing is, they often don’t rely on infrastructure or conventional business models at all.